Delonix Bioworks Receives Dual Regulatory Clearance for Novel MenB Vaccine DX-104 in China and Australia
核心洞察
Delonix Bioworks (搜索) has received IND clearance from China's NMPA and completed CTN procedures in Australia for DX-104 (搜索), a novel Group B meningococcal vaccine candidate.
The engineered vaccine uses Delonix's proprietary OMV Plus® platform and demonstrated robust serum bactericidal antibody responses without external adjuvants in preclinical studies.
Phase I clinical trials will evaluate safety and immunogenicity, targeting a significant unmet need as serogroup B accounts for approximately 50% of invasive meningococcal disease cases globally.
Delonix Bioworks (搜索), a clinical-stage biotechnology company developing next-generation bacterial vaccines, has achieved a significant regulatory milestone with dual clearances for its Group B meningococcal (MenB) vaccine candidate DX-104 (搜索). The company received Investigational New Drug (IND) clearance from China's National Medical Products Administration (NMPA) in February 2026, following successful completion of Clinical Trial Notification (CTN) procedures and ethics committee approval in Australia in January 2026.
The dual regulatory approvals enable Delonix to initiate Phase I clinical trials in the near term to evaluate the safety and immunogenicity of DX-104 (搜索) in human subjects, marking the company's transition into clinical-stage development.
Addressing Critical Unmet Medical Need
Invasive meningococcal disease (IMD) represents a life-threatening bacterial infection that disproportionately impacts infants, adolescents, and young adults. Serogroup B has emerged as a predominant cause of IMD globally, accounting for approximately 50% of cases with a rising prevalence trend. Despite the commercial success of existing vaccines like GSK's Bexsero® and Pfizer's Trumenba®—with Bexsero recording approximately $1.58 billion in sales in 2025—significant global gaps in access and strain coverage remain.
Novel OMV Plus® Platform Technology
DX-104 (搜索) is an engineered MenB vaccine candidate developed using Delonix's proprietary OMV Plus® platform. The platform leverages precisely engineered outer membrane vesicles (OMVs) with intrinsic adjuvant properties to optimize immunogenicity. This approach represents a differentiated strategy in the meningococcal vaccine landscape.
In preclinical studies, DX-104 (搜索) induced robust serum bactericidal antibody (SBA) responses without the need for external adjuvants, demonstrating the potential efficacy of the OMV Plus® platform. The vaccine candidate has also achieved commercial-scale production with high batch-to-batch consistency, ensuring a reliable global supply chain as the candidate advances toward potential commercialization.
Strategic Global Development
"The dual regulatory clearances in China and Australia mark a transformative milestone for Delonix Bioworks (搜索) as we transition into a clinical-stage company," said Qiubin Lin, CEO and Founder of Delonix Bioworks. "This is a crucial step in our global strategy to deploy engineered bacterial vaccines that are designed to be highly immunogenic, well-tolerated, and scalable. We are committed to addressing the urgent unmet medical needs of patients worldwide."
The regulatory clearances position Delonix to compete in a substantial market opportunity, as demonstrated by the commercial success of existing MenB vaccines. The company's focus on engineered bacterial vaccines with enhanced immunogenicity profiles could potentially address current limitations in strain coverage and global access that characterize the current treatment landscape.